Literature DB >> 12944191

Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms.

Stepan Vesely1, Tomas Knutson, Jan-Erik Damber, Mauro Dicuio, Christer Dahlstrand.   

Abstract

OBJECTIVES: To estimate the relationship between age and the values of different diagnostic tests in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic enlargement (BPE) and to compare prostate growth curves between the normal population sample, healthy men and men with LUTS.
MATERIAL AND METHODS: A series of 354 men (mean age 70.2 years; range 45-91 years) with LUTS due to BPE were stratified into seven age groups and reviewed retrospectively. All patients underwent a standard evaluation, involving determination of the International Prostate Symptom Score (IPSS), digital rectal examination, uroflowmetry, determination of the prostate-specific antigen (PSA) level and transrectal ultrasonography. Descriptive statistics were used to describe all the variables and Spearman's correlation test was used to evaluate the relationships between them.
RESULTS: The mean prostate volume was 40.1 (+/-23.9) cm(3) and mean PSA concentration 3.9 (+/-4.2) ng/ml. Both values increased progressively from 27.5 ml and 1.5 ng/ml, respectively in the <54 years age group to 48.2 ml and 5.4 ng/ml, respectively in the <80 years age group. However, in the 75-79 years age group there was a decrease in both prostate volume and symptom score; PSA concentration remained unchanged and maximal flow rate increased slightly. A statistically significant but weak correlation was found between prostate volume and age (r = 0.25, p < 0.0001) and between PSA and age (r = 0.28, p < 0.0001). Prostate volume correlated positively with serum PSA (r = 0.54, p < 0.0001). The correlations between maximum flow rate and age, prostate volume, PSA and IPSS were r = -0.21, p < 0.0001; r = -0.18, p < 0.0006; r = -0.29, p < 0.0001; and r = 0.14, p < 0.0098, respectively.
CONCLUSIONS: These data confirm that prostate volume and serum PSA concentration are significantly correlated and increase with advanced age. The correlations between uroflowmetry (Qmax) and age, prostate volume, serum PSA and IPSS were also significant. However, there was no relationship between symptoms and objective measures of BPE. The increase in different parameters of the severity of benign prostatic hyperplasia with advanced age is not continuous. The prostate volume alone is not useful in the estimation of disease severity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944191     DOI: 10.1080/00365590310014760

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  18 in total

1.  New technique for prostate volume assessment.

Authors:  Mohamad Habes; Jeanette Bahr; Thilo Schiller; Jens-Peter Kühn; Laura Hoppe; Martin Burchardt; Wolfgang Hoffmann
Journal:  World J Urol       Date:  2013-12-05       Impact factor: 4.226

2.  Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Siobhan Sutcliffe; Robert L Grubb Iii; Elizabeth A Platz; Lawrence R Ragard; Thomas L Riley; Sally S Kazin; Richard B Hayes; Ann W Hsing; Gerald L Andriole
Journal:  BJU Int       Date:  2012-03-19       Impact factor: 5.588

Review 3.  [Diagnostics of benign prostate syndrome].

Authors:  M Seitz; A Herlemann; G Magistro; C G Stief
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

4.  Experience with uroflowmetry in evaluation of lower urinary tract symptoms in patients with benign prostatic hyperplasia.

Authors:  Sanjeev Singla; Ramneesh Garg; Ankit Singla; Sandeep Sharma; Jasdeep Singh; Pulkit Sethi
Journal:  J Clin Diagn Res       Date:  2014-04-15

5.  Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men.

Authors:  Anastasios Karatzas; Vassilios Tzortzis; Eirini Giannatou; Stavros Gravas; Ioannis Zachos; Athanassios Oeconomou; Michael Melekos; Aspasia Tsezou
Journal:  Mol Biol Rep       Date:  2013-09-21       Impact factor: 2.316

6.  Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.

Authors:  Kang Jun Cho; Se Hee Kang; Hyo Sin Kim; Jun Sung Koh; Joon Chul Kim
Journal:  Int Neurourol J       Date:  2011-09-30       Impact factor: 2.835

7.  Clinical and Pathological Characteristics of Hard Nodules Resistant to Morcellation During Holmium Laser Enucleation of the Prostate.

Authors:  Songzhe Piao; Min Soo Choo; Yue Wang; Young Ju Lee; Jungbum Bae; Seung-June Oh
Journal:  Int Neurourol J       Date:  2015-06-29       Impact factor: 2.835

8.  Establishment of Reference Ranges for Prostate Volume and Annual Prostate Volume Change Rate in Korean Adult Men: Analyses of a Nationwide Screening Population.

Authors:  Jinsung Park; Dong-Gi Lee; Beomseok Suh; Sung Yong Cho; In Ho Chang; Sung Hyun Paick; Hyung-Lae Lee
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

9.  Physical activity and benign prostatic hyperplasia-related outcomes and nocturia.

Authors:  Kathleen Y Wolin; Robert L Grubb; Ratna Pakpahan; Lawrence Ragard; Jerome Mabie; Gerald L Andriole; Siobhan Sutcliffe
Journal:  Med Sci Sports Exerc       Date:  2015-03       Impact factor: 5.411

10.  Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.

Authors:  Melissa M Norström; Emelie Rådestad; Berit Sundberg; Jonas Mattsson; Lars Henningsohn; Victor Levitsky; Michael Uhlin
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.